Oligo Chemistry & Therapeutics
Online Symposium
27 September 2024 | Online, BST (UTC+1)
Bringing together top minds from across the globe for focused discussions on oligo discovery & therapeutic development
Sponsored By
A&M STABTEST a full service CRO for Biopharmaceuticals, ASO and mRNA A&M STABTEST is a full-service CRO dedicated to analytical development, stability and release testing of Biopharmaceuticals and antisense oligonucleotides (ASO) and mRNA since 1995. Located in the heart of Europe, our team of 340 highly skilled staff take care of all aspects from sample logistics and storage, functional testing of devices, pharmaceutical testing incl. cell-based potency testing, to LC-MS based product characterization. As a company owned and managed by scientists, we take pride in being recognized as an innovative science-driven organization, capable of developing analytical solutions for our clints enabling them to take their innovative drugs to the market. With all Biopharma, ASO and mRNA services performed at one site, we truly offer a “Under-One-Roof-Shop” for highest quality pharmaceutical testing. For more information, please contact Dr. Steven Am Watt at steven.watt@am-labor.de
Key Topics Covered
- Overcoming oligonucleotide therapeutic challenges
- Optimising targeted oligo delivery
- Analytical methods for oligonucleotides:
» Liquid chromatography
» Mass spectrometry - Assessing oligonucleotide impurity
Benefits of Attending
- Meet with global key innovators in a focused symposium to hear the latest case studies in oligo chemistry & therapeutics. This programme takes a deep dive into best practice oligo chemistry & development approaches & technological advancements, bringing together thought leaders from across the globe for focused discussions & networking
- Gain a comprehensive understanding of oligo chemistry & targeted delivery approaches. Key opinion leaders will be covering peptide-oligo conjugation, modification chemistry & advanced synthesis tools & technologies
- Take a deep dive into the commercialisation of oligo therapeutics. Discuss the latest applications of these therapeutics in the clinical field including case studies from various disease areas and creating a discourse on what the next application may be
- Followed by the release of the ‘Harnessing Oligo Chemistry & Therapeutics Development with Best Practice Approaches’ report detailing key insights, methodologies, and emerging trends discussed during the event for leveraging oligo chemistry & therapeutics effectively
Latest Resources
GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
GHR’s total investment in C2N has now broken $50 million since 2020.
Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.
Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy
SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.
Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma
The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Life Science Players Join €23m European Project for Precision Medicine, PRECISEU
The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.
Meet Our Expert Speakers
Oligo Chemistry & Therapeutics Online Symposium again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Confirmed speakers include:
Anna Rydzik
Principal Scientist,
xx
Brooke Koshel
Director, Process Development,
Wave Life Sciences
Isaac Marks
Senior Scientist, Chemistry,
Avidity
Sasha Ebrahimi
Principal Investigator and Associate Fellow,
GSK
Ulrike Rieder
Scientific Lead,
Novartis
Register Your Interest
Submit your details and a member of our team will be in touch